

DISTRIBUTION OF EXTENDED SPECTRUM β -LACTAMASE GENES AMONG *PROTEUS MIRABILIS* ISOLATED FROM CLINICAL SPECIMENS IN DUHOK CITY, KURDISTAN REGION, IRAQ

Haval Mohammed Khalid ^{a,*}, Najim Abdullah Yassin ^b^a Dept. of Biology, Faculty of Science, University of Zakho, Kurdistan Region, Iraq - (Haval.khalid@uoz.edu.krd)^b Dept. Microbiology, Faculty of Medical Science, University of Duhok, Kurdistan Region, Iraq.**Received: Oct. 2016 / Accepted: Feb. 2017 / Published: Mar. 2017**<https://doi.org/10.25271/sjuoz.2017.5.1.444>**ABSTRACT:**

Extended Spectrum Beta Lactamase-among *Proteus mirabilis* strains recorded high incidence leaving few therapeutic options of potential infections. The purpose of current study was to assess the prevalence of antibiotic resistance among Extended Spectrum Beta Lactamases (ESBL) producing *P. mirabilis*, in addition to molecular characterization of the ESBL gene-types using PCR. All isolates were fully identified, checked for antibiotic susceptibility and ESBL production using, double disk synergy phenotypic method. Positive ESBL-producing isolates were subjected to PCR assay using specific primers for detection of CTX-M, TEM and SHV genes. The majority of the isolates exhibited absolute susceptibility (100%) to both meropenem and ertapenem and high susceptibility (95%) to imipenem, while co-resistance were expressed toward cefotaxime, ceftazidime, ceftriaxone and other non-lactam antibiotics. Out of 37 isolates, 21(57%) were ESBL-producers and using a double-disc synergy test (DDST). Using molecular-based PCR, CTX-M (81%), TEM (57%) and SHV (24%) were determined among ESBL-positive. CTX-M was predominant and circulating among phenotypic multiple resistant strains. Moreover, coexistence of CTX-M and TEM gene was more frequent combination. The study highlighted the increasing levels of low antibiotic susceptibility among *P. mirabilis* harbored ESBL genes at Duhok city and also confirms that a high level of *bla*CTX-M-positive ESBL isolates is circulating in this area.

KEYWORDS: *Proteus mirabilis*, ESBL, PCR.**1. INTRODUCTION****1.1 Instructions**

In enterobacteriaceae, Extended Spectrum Beta Lactamases (ESBL) are mainly produced by *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* strains responsible for nosocomial infection. These strains are disseminated worldwide (Mabilat and Courvlin, 1990). *Proteus mirabilis* is unique species among enterobacteriaceae and is the common cause of several types of infections predominantly urinary tract infections (UTI), mainly after prolonged hospitalization. ESBL are enzymes which are formed by gram negative bacilli which facilitate resistance to the penicillins, cephalosporins and the monobactams and are commonly known as Enterobacteriaceae (Kaur and Aggarwal, 2013). *K. pneumoniae* and *E. coli* are well-known pathogens producing ESBL enzymes particularly those isolates from hospital location. Recently, *P. mirabilis* isolates recorded high level of incidence of ESBL-production, namely in hospital environments, leading to uncontrolled and little treatment options of various infections (Tonkic *et al.*, 2010). This study highlighted the diversity of β -lactamases in *P. mirabilis*; firstly TEM defined then AmpC type β -lactamases reported and recently non-TEM and SHV-derived ESBL have been described (Chanal *et al.*, 2000).

Data on ESBL-producing isolates of *P. mirabilis* in Duhok city are limited, so the goals of the current work is to find out the rates of antibiotic-susceptibility among *P. mirabilis* isolates in various clinical specimens among inpatients at Azadi Teaching Hospital, Duhok city and molecular characterization of the ESBL genes of the isolates using PCR assay.

2. MATERIALS AND METHODS**2.1 Bacterial strains**

A total of 37 consecutive non-duplicate *P. mirabilis* were isolated from the clinical specimens including urine, wound and the middle ear of patients admitted to Azadi Teaching Hospital, Duhok city from December 2014 to May 2015.

2.2 Bacterial Identification

Bacterial isolates were identified using conventional microscopic and biochemical tests: Gram staining, motility, swarming behavior, indole production, phenylalanine dehydrogenase, ornithine decarboxylase, gas production from glucose, H₂S production, urease, tryptophan deaminase, lysine decarboxylase, and citrate and lactose utilization (Koneman *et al.*, 1992).

2.3 Antimicrobial Susceptibility Testing

The isolated bacteria were identified according to the standard method of biochemical tests. Antibiotic-susceptibility rates against different antibiotics were determined by the method of disc diffusion assay using Mueller–Hinton agar (CLSI, 2006).

2.4 Determination of ESBL Production

Determination of the ability of the production of ESBL was performed through double-disc synergy test (DDST). Disks containing cefotaxime (30 μ g), ceftazidime (30 μ g), and ceftriaxone (30 μ g) were placed 25 mm (center to center) from an amoxicillin-clavulanic acid disk (30 and 10 μ g, respectively), incubated at 35°C overnight. Probable indication of ESBL production was observed through a synergy between any one of

* Corresponding author

the cephalosporins and amoxicillin/clavulanic acid (CLSI, 2006). The ESBL-producing *P. mirabilis* isolates were further analyzed and their ESBLs were molecularly characterized.

2.5 Detection of ESBL Genes by Polymerase Chain Reaction

The genomic DNA was extracted from 21 positive ESBL isolates of *P. mirabilis* using DNA extraction kit (aidgen,

Korea). The ESBL genes, TEM, SHV, CTX-M were detected using specific pair of primers for each gene (table 1), (EUROFINS, mwg, operon, Germany). Primer sequences and amplification settings were performed as described by Yun-Tae *et al.* (2006); Adamus-Bialek *et al.* (2009). The presence of the PCR product was confirmed electrophoretically using 1.5% (w/v) of agarose. Molecular marker (100-1500bp) was used to determine the molecular weight of the PCR product.

Table 1. Primers used for the detection of ESBL genes

Primer	Primer sequences	Amplicon size
CTX-M/F CTX-M/R	5'-CGCTTTGCGATGTGCAG-3' 5'-ACCGCGATATCGTTGGT 3'	551 bp
TEM/F TEM/R	5'-ATAAAATTCCTGAAGAAGACGAAA-3' 5'-GACAGTTACCAATGCTTAATC -3'	1080 bp
SHV/F SHV/R	5'-TCGTTATGCGTTATATTCGCC-3' 5'-GGTTAGCGTTGCCAGTGCT -3'	861 bp

3. RESULTS

The majority of *P. mirabilis* isolates 20/37 (54%) were recovered from urine followed by 10/37(27%) isolates from wounds and 7/37(19%) from the middle ear.

3.1 Antibiotic Susceptibility Rates

Table (2) indicates that 21/37 (57%) from the tested isolates were producers of ESBL using a double-disc synergy test, and all of them exhibited absolute susceptibility (100%) to both

meropenem and ertapenem and high susceptibility (95%) to imipenem. On the other hand, moderate to low susceptibility rates were expressed against amoxicillin-clavulanic acid, cefepime, ceftazidime, ceftriaxone and cefotaxime which were 61, 38, 19, 19, and 0%, respectively. While low susceptibility rates were observed with other non-Beta-lactams tested antibiotics like ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin and amikacin. Moreover, 66.6% of ESBL isolates expressed Multiple-Drug Resistance (MDR) phenotype. While, non-ESBL-producer isolates recorded high to moderate susceptibility rates toward tested antibiotics used in this study as shown in table (2).

Table 2. Antibiotic susceptibility rates of all 37 *P. mirabilis* isolates included ESBLs-positive and non-ESBL producers

Antibiotics	Symbol	ESBL-positive (n=21 isolates) (%*)	Non-ESBL-producer (n=16 isolates) (%*)
Amoxicillin+clavulanic acid	AMC	61	94
Cefepime	FEP	38	94
Ceftazidime	CAZ	19	94
Ceftriaxone	CRO	19	94
Cefotaxime	CTX	0	81
Imipenem	IMP	95	100
Meropenem	MEM	100	100
Ertapenem	ERT	100	100
Amikacin	AK	57	63
Gentamicin	CN	33	38
Trimethoprim-sulfamethoxazole	SXT	33	25
Ciprofloxacin	CIP	24	25
Amoxicillin	AX	10	31
Nitrofurantoin	F	10	31
Ampicillin	AM	10	19
		66.6%**	40%**

* Susceptibility rate

** Percentage of resistance collectively to all used antibiotics

3.2 Detection of ESBL genes by PCR

The frequency of CTX-M, TEM and SHV singly or multiply among ESBL-positive isolates were, 17/21, 81(%), 12/21, (57%) and 5/21, 24(%), respectively. Co-presence of all of the three gene groups was significantly more encountered among

P. mirabilis isolates. In 7(33.3%) of the isolates, simultaneous appearance of TEM + CTX-M combination was predominant genes coexistence among isolates comparing with SHV+ CTX-M and SHV+CTX-M+TEM combination that recorded at a rate of 9.5% for each as shown in table (3) figures (1,2, and 3).




Figure 1. PCR amplification of TEM




Figure 2. PCR amplification of SHV




Figure 3. PCR amplification of CTX-M

3.3 Prevalence of ESBL genes among multiple antibiotics-resistant-ESBL-positive *P. mirabilis* isolates

The gene CTX-M was the most prevalent ESBL gene either singly or in combination with SHV and TEM. CTX-M was the most frequently detected gene within isolates particularly those expressed high resistance toward tested antibiotics in this study. Isolates number 18 and 20 simultaneously recorded 87% and 80% resistance rates and harbored CTX-M as a single gene and TEM+CTX-M+SHV in combination genes, respectively. The least frequently detected genes were SHV, except for isolates number 7 that showed 73% resistance rate and harbored SHV only as shown in table (4).

Table 3. Occurrence of single and multiple ESBL genes among positive-ESBL *P. mirabilis* isolates

ESBL gene types	No. (%) of isolates
TEM only	3 (14.2)
SHV only	1 (5)
CTX-M only	6 (28.5)
TEM+CTX-M	7 (33.3)
SHV+CTX-M	2 (9.5)
TEM+SHV+CTX-M	2 (9.5)
Total	21

Table 4. Prevalence of ESBL genes among 21 multiple-antibiotics resistant-ESBL-positive *P. mirabilis* isolates

Isolates	Resistance rates to selected antibiotics %	ESBL harboring genes
1	67	TEM+CTX-M
2	67	TEM+CTX-M
3	53	CTX-M+SHV
4	47	CTX-M
5	60	CTX-M
6	67	TEM+CTX-M+SHV
7	73	SHV
8	60	TEM+CTX-M
9	60	CTX-M
10	40	TEM+CTX-M
11	53	TEM+CTX-M
12	40	CTX-M
13	53	CTX-M
14	67	TEM+CTX-M
15	53	CTX-M
16	47	CTX-M+SHV
17	67	CTX-M
18	87	CTX-M
19	53	CTX-M
20	80	TEM+CTX-M+SHV
21	60	TEM+CTX-M

4. DISCUSSION

Nowadays, there is an increasing use of the broad-spectrum antimicrobial agents, which increased the incidence of ESBL-producing enterobacteriaceae worldwide at a worrying rate. Currently, the major task for infection control teams is the prevention of the appearance and the spread of ESBL-producing enterobacteriaceae (CLSI, 2006). Some isolates of *P. mirabilis* are susceptible to β -lactams, but resistance may be acquired due to the production of β -lactamases (Hassan *et al.*, 2013). In the present study, out of 37 isolates of *P. mirabilis*, 21(57%) were ESBL producing using phenotypic double disk method. This result is in accordance with other studies performed in Iraq, in which rates of 34.6, 40, 42 and 55.5% of *P. mirabilis* were ESBL producers, respectively (Jarjees, 2006; Al-Haidari, 2010; Hussein, 2013; Ahmad and Ali, 2014). The result of the current study indicates that our area is among the countries having high level of ESBL production among *P. mirabilis* isolates than other places like Saudi Arabia, Croatia, Poland France and Greece which have 3.1, 12.6, 14.5, 3.3 and 5.9% , respectively (Nijssen *et al.*, 2004; Alghamdi 2006; Empel *et al.*, 2008; Tonkic, *et al.*, 2010; Al-Haidari 2010). This may be due to the differences in the type and amount of consumption of antibiotics, indicating that patients were infected with ESBL producing *P. mirabilis* which might increase the risk of treatment failure with expanded spectrum β -lactamase antibiotics. These could be also due to the fact that in more developed countries effective policies for the control of antimicrobial agents are present, which successfully prevents the occurrence of ESBL. Additionally, the rates of the drug resistance were higher in the ESBL producers than in the non-ESBL producers in this study. Observations of a high level of antibiotic resistance among strains analyzed in the present study are disturbing, but they are in agreement with previously published results, that showed high susceptibility of ESBL *P.*

mirabilis to meropenem, ertapenem and imipenem (Ojdana *et al.*, 2014). The present study also documents that the ESBL producers are also co-resistant to other non- β -lactam antibiotics and their susceptibility was low, to Ciprofloxacin (24%), gentamicin (33%), trimethoprim-sulfa (33%), and are only 10% susceptible to amoxicillin and ampicillin. These results agree with those of Jarjees (2006); Tonkic *et al.* (2010), Hussein (2013); Ahmad and Ali (2014). Moreover, 66.6% of ESBL-positive strains in this study showed simultaneous resistance to both β -lactams and antibiotics of other groups that could be defined as multidrug-resistant strains (MDR). This feature is already has been observed by Poirel *et al.* (2000); Luzzaro *et al.* (2001); Ojdana *et al.* (2014), which might be due to an association between ESBL production and resistance to aminoglycosides, because ESBL genes are near or are at close places to multiple resistances gene cassettes that coordinated the occurred expression. In enterobacteriaceae, resistant genes are located close to each other on the plasmids, where genes responsible for resistance to different groups of antibiotics may be located in a close neighborhood thus; they may be transmitted at the same time to other bacteria (Ishii *et al.*, 1995; Leverstein-vanHall *et al.*, 2002; Karisiki *et al.*, 2006). So, this is considered as the biggest problem in the treatment of infections caused by gram-negative bacilli.

The gene CTX-M variants have displaced TEM and SHV enzymes as the predominant β -lactamases producers that reflects remarkable increase in this genotype in this area of Iraq. This is consistent with many published reports worldwide, for example, a study in Japan reported the prevalence of CTX-M genotypes among ESBL-producing *P. mirabilis* isolates (Leverstein-vanHall *et al.*, 2002; Nakamura *et al.*, 2012). A similar finding reported in Poland by Ojdana *et al.* (2014), Polish assistants ensured also that their isolates of *P. mirabilis* were generally producing CTX-M (Empel *et al.*, 2008). Similar data was reported by Moghaddam *et al.* (2014). This study is inconsistent to a study in Baghdad, Iraq in which high prevalence of TEM was reported (Al-Jubori *et al.*, 2012). Moreover, studies from France, India, Croatia, Italia and China illustrated the predominance of TEM genotype (Chanal *et al.*, 2000; Tonkic *et al.*, 2010; Kaur and Aggarwal, 2013, and Huang *et al.*, 2014). Furthermore, some other studies concluded the absolute circulation of the TEM genotype (Endimiani *et al.*, 2005; Perilli *et al.*, 2002). While TEM ESBL was not detected in a study conducted in Saudi Arabia (Hassan and Abdalhamid, 2014). SHV genotype was less encountered in the present study; similarly other studies did not succeed in detecting this gene (Al-Jubori *et al.*, 2012; Hassan *et al.*, 2013; Ojdana *et al.*, 2014). The presence of more than one ESBL in a single isolate was frequently detected in addition to the coproduction of all the three genes (Coexistence of CTX-M and TEM genes) in 7/21 (33%). This scenario was also clarified by Hassan and Abdalhamid (2014). Also, TEM genotype was predominant genotype among ESBL *P. mirabilis* producers in other studies performed in France, India, Croatia and Italy (Chanal *et al.*, 2000; Tonkic *et al.*, 2010; Nakamura *et al.*, 2012; Kaur and Aggarwal, 2013). The coexistence of CTX-M and TEM highlights the growing of the complexity of antibacterial resistance problems, and the reasons for this situation require further investigation.

The analysis of the resistant *bla* genes revealed that *P. mirabilis* isolates carrying the *bla*CTX-M gene, was the most prevalent phenotype of resistance towards selected antibiotics. It is noteworthy that isolates number 18 and 20 simultaneously recorded 87% and 80% resistance rates and harbored CTX-M as a single gene and TEM+CTX-M+SHV in combination, respectively. In addition, the dominance of CTX-M gene-type among high resistance isolates and multiple-resistant drugs (MRD) was revealed. Same data were reported by Nijssen *et al.* (2004); Ojdana *et al.* (2014); Huang *et al.* (2014), who

attributed it to the likelihood of further distribution of *bla* CTX-M gene among multiple-resistant *P. mirabilis* strains. In this study, SHV gene-type was the least frequently detected gene; only detected in isolate number 7 which showed 75% resistance to tested antibiotics. The variability of dissemination of ESBL in *P. mirabilis* retells us it's significant to detect the genotype and the antimicrobial susceptibility pattern which are critical in the treatment of infections caused by ESBL-positive bacteria.

5. CONCLUSION

The increasing levels of resistance to antibiotics by ESBL-producing *P. mirabilis* strains in Duhok city are alarming and denote severe helpful questions. This study demonstrates the presence of a high level of *bla*CTX-M-positive ESBL isolates which are circulating in this area. The tendency of multidrug-resistant profiles associated with the recovery of the *bla*CTX-M gene is worrying. An indiscriminate use of the higher antibiotics should be restricted as far as possible and further monitoring and screening studied for ESBL production must be included in all clinical laboratories in this area.

REFERENCES

- Adamus-Bialek, W.; Wojtasik, A.; Majchrzak, M.; Sosnowski, M. and Parniewski, P. (2009). (CGG) 4- based PCR as a novel tool for discrimination of uropathogenic *Escherichia coli* strains: Comparison with enterobacterial repetitive intergenic consensus-PCR. *Journal of Clinical Microbiology*, 47: 3937–3944.
- Ahmad, S.S. and Ali, F.A. (2014). Detection of ESBL, AmpC and metallo beta-lactamase mediated resistance in gram-negative bacteria isolated from women with genital tract infection. *European Scientific Journal*, 10:193-209.
- Alghamdi, A. (2006). Detection of Criteria of *Proteus mirabilis* isolates from hospital and community-acquired infections and their roles in antibiotic resistance. *Egyptian Journal of Medical Microbiology*, 15: 55-64.
- Al-Haidari, C.H. (2010). Microbiological study of urinary tract infection, Antibiotics susceptibility pattern and extended spectrum beta lactamase prevalence among children in Erbil city. M.Sc. Thesis, College of Medicine, Hawler Medical University-Iraq.
- Al-Jubori, S.S.; Hamed, S.L. and Al-Kaabi, M.H. (2012). Determination of genetic factors controlling β -lactamase enzyme related to *bla* TEM and *bla* SHV families using the polymerase chain reaction. *Iraqi Journal Biotechnology*, 2: 377- 388.
- Chanal, C.; Bonnet, R.; champs, C. D.; Sirot, D.; Labia, R. and Sirot, J. (2000). Prevalence of β -lactamases among 1,072 clinical strains of *Proteus mirabilis*: a 2-year survey in a French hospital. *Antimicrobial Agents and Chemotherapy*, 44: 1930–1935.
- Clinical and Laboratory Standards Institute (2006). Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute.
- Empel, J.; Baraniak, A.; Literacka, E.; Mroćka, A.; Fiett, J.; Sadowy, E. (2008). Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in enterobacteriaceae isolates from Polish hospitals. *Antimicrobial Agents Chemotherapy*, 52: 2449–2454.
- Endimiani, A.; Luzzaro, F.; Brigante, G.; Perilli, M.; Lombardi, G. and Amicosante, G. (2005). *Proteus mirabilis* bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. *Antimicrobial Agents and Chemotherapy*, 49: 2598–605.
- Hassan, H. and Abdalhamid, B. (2014). Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. *Journal of Infection in Developing Countries*, 8:282-288.
- Hassan, M.I.; Alkharsah, K.R.; Alzahrani, A.J.; Obeid, O.E.; Khamis, A.H. and Diab, A. (2013). Detection of extended spectrum beta-lactamases-producing isolates and effect of AmpC

- overlapping. *Journal of Infection in Developing Countries*, 7: 618-629.
- Huang, Y.; Xu, Y.; Wang, Z. and Lin, X. (2014). Antimicrobial resistance and genotype analysis of Extended-Spectrum- β -Lactamase-Producing *Proteus mirabilis*. *Open Journal of Clinical Diagnostics*, 4: 57-62.
- Hussein, A.A. (2013). Phenotypic detection of Extended Spectrum Beta Lactamase production in *P. mirabilis* isolation from patients with significant bacteriuria in Najaf province. *Kufa Medical Journal*, 9:149-156.
- Ishii, Y.; Ohno, A.; Taguchi, H.; Imago, S.; Ishiguro, M. and Matsuzwa, H. (1995). Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A, Beta-Lactamase isolated from *Escherichia coli*. *Antimicrobial Agent and Chemotherapy*, 39:2269-2275.
- Jarjees, R.K. (2006). Bacteriological study of the incidence of genitourinary tract infection in diabetic women in Erbil. M.Sc. Thesis, College of Science, University of Salahaddin-Iraq.
- Karisiki, E.; Ellington, M.J.; Pike, R.; Warren, R.E.; Livermore, D.M. and Woodford, N.(2006). Molecular characterization of plasmids encoding CTX-M-15 β -lactamases from *Escherichia coli* strains in the United Kingdom. *Journal of Antimicrobial Chemotherapy*, 58:665-668.
- Koneman, E.W; Allen, S.D.; Janda, W.M.; Schreckenberger, P.C. and Winn, W.C. (1992). *Color Atlas and Textbook of Diagnostic Microbiology*. JB: Lippincott. Philadelphia, Washington.
- Leverstein-van Hall, M.A.; Box, A.T.; Blok, H.E.; Paauw, A.; Fluit, A.C. and Verhoef, J. (2002). Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant enterobacteriaceae in a clinical setting. *Journal of Infectious Diseases*, 186:49–56.
- Luzzaro, F.; Perilli, M.; Amicosante, G.; Lombardi, G.; Belloni, R.; Zollo, A.; Bianchi, C. and Toniolo, A. (2001). Properties of multidrug-resistant, ESBL producing *Proteus mirabilis* isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. *International Journal of Antimicrobial Agents*, 17:131-135.
- Mabilat, C. and Courvalin, P. (1990). Development of oligotyping for characterization and molecular epidemiology of TEM beta-lactamases in members of the family enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, 34:2210-2216.
- Kaur, M. and Aggarwal, A. (2013). Occurrence of the CTX-M, SHV and the TEM Genes among the Extended Spectrum β -Lactamase Producing isolates of enterobacteriaceae in a Tertiary Care Hospital of North India. *Journal of Clinical and Diagnostic Research*, 7:642-645.
- Tonkic, M.; Mohar, B.; Sisko-Kraljević, K.; Mesko-Meglic, K.; Goić-Barisić, I.; Novak, A.; Kovacić, A. and Punda-Polić, V. (2010). High prevalence and molecular characterization of Extended-Spectrum β -Lactamase-Producing *Proteus mirabilis* strains in southern Croatia. *Journal of Medical Microbiology*, 59:1185–1190.
- Nakamura, T.; Komatsu, M.; Yamasaki, K.; Fukuda, S.; Miyamoto, Y.; Higuchi, T.; Ono, T.; Nishio, H.; Sueyoshi, N.; Kida, K.; Satoh, K.; Toda, H.; Toyokawa, M.; Nishi, I.; Sakamoto, M.; Akagi, M.; Nakai, I.; Kofuku, T.; Orita, T.; Wada, Y.; Zikimoto, T.; Koike, C.; Kinoshita, S.; Hirai, I.; Takahashi, H.; Matsuura, N. and Yamamoto, Y. (2012). Epidemiology of *Escherichia coli*, *Klebsiella* Species, and *Proteus mirabilis* strains producing Extended-Spectrum β -Lactamases from clinical samples in the Kinki Region of Japan. *American Journal of Clinical Pathology*, 137: 620-626.
- Moghaddam, M. N.; Beidokhti, M. H. ; Jamehdar, S. A. and Ghahraman, M. (2014). Genetic properties of blaCTX-M and blaPER β -lactamase genes in clinical isolates of enterobacteriaceae by polymerase chain reaction. *Iranian Journal of Basic Medical Sciences*, 17:378-383.
- Nijssen, S.; Florijn, A.; Bonten, M.J.; Schmitz, F.J.; Verhoef, J. and Fluit, A.C. (2004). Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European enterobacteriaceae isolates. *International Journal of Antimicrobial Agents*, 24:585–591.
- Ojdana, D.; Sacha, P.; Wiczorek, P.; Czaban S. ;Michalska, A.; Jaworowska, J.; Jurczak, A. ; Poniatowski, B. and Tryniszewska, E. (2014). The Occurrence of blaCTX-M, blaSHV, and blaTEM Genes in Extended-Spectrum β -Lactamase-Positive Strains of *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* in Poland. *International Journal of Antibiotics*, 44:1-6.
- Perilli, M.; Dell'Amico, E.; Segatore, B.; de Massis, M. R.; Bianchi, C.; Luzzaro, F.; Rossolini, G. M.; Toniolo, A.; Nicoletti, G. and Amicosante, G. (2002). Molecular characterization of Extended-Spectrum -L β -Lactamases produced by nosocomial isolates of enterobacteriaceae from an Italian nationwide survey. *Journal of Clinical Microbiology*, 40:611–614.
- Poirel, L.; LeThomas, I.; Naas, T.; Karim, A. and Nordman, P. (2000). Biochemical sequence analyses of GES-1, a novel class A Extended Spectrum β -Lactamase, and the class 1 integron IN52 from *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy*, 44:622-632.
- Yun-Tae, K.; Kim, T.U. and Baik, H. S. (2006). Characterization of Extended Spectrum β -Lactamase genotype TEM, SHV and CTX-M producing *Klebsiella pneumoniae* isolated from clinical specimens in Korea. *Journal of Microbiology and Biotechnology*, 16:889-895.

كورتيا ليكولين:

بەلاف بوونا جينين بيتا لاکتيمهيز يا بەرفره ل ناف بەکترىايين *Proteus mirabilis* ل نمونهييين جھى ل باژيرى دھوکن / ھەرئما کوردستانا عيراقى بوونا ئەنزيمن بيتا لاکتيمهيزى جوريى کەفانى بەرفره (ESBL) ل ناف ميکروبي *Proteus mirabilis* تومارەکا مەزن ئەنجام دايە کو بويە ئەگەريى نزمکرناکاريى ئەنتى بايوتيکا ب تاييه تي ل تووشيونين ب ھيز، نارمانجا في ئەکولينى ھەلسانگاندا خوراگريا ئەنتى بايوتيکانه ل سەر ميکروبي *Proteus mirabilis* خودان ئەنزيمن بيتا لاکتيمهيزى جوريى کەفانى بەرفره (ESBL)، ھەرھەسا نياسينا سالوخەييين جينين نە ديار ل فان ئەنزيماں داب، ريکا PCR، ھەمى بەکترىايين جوداکرى بو خویندننى ھاتنە نياسين و دەستنيشانکرن و ھەرھەسا تاقيرکريين خوراگرتنا بەکترىا بو ئەنتى بايوتيکان و بەرھەمئيانا ئەنزيمن بيتا لاکتيمهيز ب ريکا double disk synergy phenotypic ھاتنە ئەنجام دان، ھەمى بەکترىايين جوداکەر پيکتينەرئى ئەنزيمن ب ريکا PCR جينين نەديار ھەک CTX-M، TEM، SHV ھاتنە دەستنيشانکرن ، ب ريکا ۱۰۰% ئەف ميکروبيين جوداکەر ھەستيار بوون بو ئەنتى بايوتيکين meropenem و ertapenem ب ريکا ۹۵% ھەستيار بوون بو imipenem ، ھەرھەسا ھەستيارەکا ھائسەنگ دگەل جوريين cefotaxime، Ceftazidime، ceftriaxone ب ريکا ۲۷ جوداکەرا ب تن ۲۱ (۵۷%) ژ جوريين (ESBL) بوون بريکا double-disc synergy، بەلئ ريکين دى ۸۱% CTX-M، 57% TEM، و ۲۴% ژ ESBL (SHV) ھاتنە نياسين . ھەرھەسا ئاشکرا بوو کو جينين CTX-M ژ ھەميان بەلافتەر بوو و ھەردوو جينين CTX-M و SHV پيکتە يين بەرەبەلاف بوو، في خویندننى ئاستى بلندى تووشبوونى ب ميکروبي *Proteus mirabilis* ژ جوريين (ESBL) ل باژيرى دھوکن ئاشکرا کر، ھەرھەسا ديار کر کو ريکا بلندا وان ژ ھەلگريين جوريين جينين CTX-M بوون.

خلاصة البحث:

الهدف من الدراسة الحاليه هو معرفة مدى انتشار نزيمة البيتا لاکتيميز واسع الطيف في جرثومة *Proteus mirabilis* والذي ادى الى ترك مجال ضيق للمضادات الحيائية المستخدمة لعلاج الاصابات القوية، اضافة الى الوصف الجزئي لانواع الجينات المشفرة لهذا الانزيم باستخدام طريقة PCR. تم تشخيص جميع العزلات بشكل كامل وبما فيها فحص حساسيتها تجاه المضادات الحيائية ونتاج انزيم البيتا لاکتيميز واسع الطيف باستخدام طريقة القرص الثنائي المتساند. كذلك تم اخضاع العزلات المنتجة لهذا الانزيم لتقنية PCR باستخدام بادينات متخصصة لتحديد الجينات المشفرة لهذا الانزيم مثل جين CTX-M، SHV، TEM. لقد اظهرت هذه الدراسة بان الغالبية المطلقة لهذه العزلات كانت حساسة (100%) تجاه المضادين meropenem و ertapenem وذات حساسية عالية (95%) تجاه imipenem بينما كانت ذات مقاومة معتدلة نحو مضادات حيائية اخرى مثل ال cefotaxime، Ceftazidime و ceftriaxone ومضادات اخرى من نوع اللا بيتا لاکتيم. من بين 27 عزلة كانت 21 (57%) موجبة لانتاج هذا الانزيم باستخدام طريقة القرص الثنائي المتساند. استخدم الطرق الجزئية المبنيه على تقنية PCR بينت نسب الجينات الثلاث كالآتي 81% (CTM)-M و 57% (TEM) و 24% (SHV) ضمن الحالات المنتجة لهذا الانزيم. كان جين CTX-M الاكثر سيادة وانتشارا بين العزلات المقاومة للمضادات الحيائية. اضافة الى ذلك كثر تواجد الجينين CTX-M و SHV معا ضمن العزلات المقاومة. كذلك سلطت الدراسة الضوء على المستويات العالية لجرثومة *Proteus mirabilis* المقاومة للمضادات والحاوية للجينات المنتجة لانزيم بيتا لاکتيميز واسع الطيف في مدينة دهوك وكذلك اكدت الدراسة بان نسبة عالية من العزلات المنتجة لهذا الانزيم والحاوية على جين CTX-M كانت الاكثر تواجدا في هذه المنطقة.